Table 4.

Clinical predictors of progestin treatment response in total cohort (n = 71).

	OR (95% CI)	P
Univariable analysis
Age (years)	0.98 (0.9–1.0)	0.11
Baseline BMI (kg/m2)	1.00 (0.9–1.1)	0.98
Postmenopausal
No	1
Yes	0.51 (0.2–1.4)	0.19
PCOS
No	1
Yes	1.58 (0.5–5.2)	0.45
T2DM
No	1
Yes	0.70 (0.3–2.0)	0.49
Histology
Endometrial cancer	1
Atypical hyperplasia	2.88 (1.0–8.0)	0.04 b
Endometrial mass lesion
No	1
Yes	0.68 (0.2–3.1)	0.61
Myometrial invasion
No	1
Yes	0.76 (1.4–4.2)	0.75
Bariatric surgery
No	1
Yes	1.78 (0.6–5.2)	0.29
% change in total body weighta
<10%	1
≥10%	3.26 (1.1–9.9)	0.04 b
Multivariable analysis adjusted for age, T2DM, histology, % change in total body weight
Histology
Endometrial cancer	1
Atypical hyperplasia	3.52 (1.1–11.0)	0.03 b
% change in total body weighta
<10%	1
>10%	3.95 (1.3–12.5)	0.02 b

^aExcludes the n = 5 women who progressed during progestin treatment.

^bSignificant at P < 0.05.